<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2681188-A1" country="EP" doc-number="2681188" kind="A1" date="20140108" family-id="47072675" file-reference-id="285710" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146586568" ucid="EP-2681188-A1"><document-id><country>EP</country><doc-number>2681188</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12777344-A" is-representative="NO"><document-id mxw-id="PAPP154848760" load-source="docdb" format="epo"><country>EP</country><doc-number>12777344</doc-number><kind>A</kind><date>20120227</date><lang>EN</lang></document-id><document-id mxw-id="PAPP168045811" load-source="docdb" format="original"><country>EP</country><doc-number>12777344.8</doc-number><date>20120227</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140551697" ucid="US-201161448412-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201161448412</doc-number><kind>P</kind><date>20110302</date></document-id></priority-claim><priority-claim mxw-id="PPC140547025" ucid="US-2012026694-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2012026694</doc-number><kind>W</kind><date>20120227</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-2085585658" load-source="docdb">C07C 255/46        20060101ALI20150311BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2085585659" load-source="docdb">C07C 253/30        20060101ALI20150311BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-2085585660" load-source="docdb">C07C 231/02        20060101AFI20150311BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1820254684" load-source="docdb" scheme="CPC">C07C2601/02        20170501 LA20170502BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989629210" load-source="docdb" scheme="CPC">C07C 253/30        20130101 LI20131214BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989647992" load-source="docdb" scheme="CPC">C07C 315/04        20130101 FI20131205BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132364337" lang="DE" load-source="patent-office">AMIDIERUNGSVERFAHREN</invention-title><invention-title mxw-id="PT132364338" lang="EN" load-source="patent-office">AMIDATION PROCESS</invention-title><invention-title mxw-id="PT132364339" lang="FR" load-source="patent-office">PROCÉDÉ D'AMIDATION</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919527647" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>MERCK SHARP &amp; DOHME</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919508317" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>MERCK SHARP &amp; DOHME CORP.</last-name></addressbook></applicant><applicant mxw-id="PPAR919019146" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Merck Sharp &amp; Dohme Corp.</last-name><iid>101321810</iid><address><street>126 East Lincoln Avenue</street><city>Rahway, NJ 07065-0907</city><country>US</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919506731" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>HUMPHREY GUY</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919515087" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>HUMPHREY, GUY</last-name></addressbook></inventor><inventor mxw-id="PPAR919012106" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>HUMPHREY, GUY</last-name><address><street>126 East Lincoln Avenue</street><city>Rahway, NJ 07065-0907</city><country>US</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919005962" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Buchan, Gavin MacNicol</last-name><iid>101125002</iid><address><street>Merck &amp; Co., Inc. European Patent Department Hertford Road</street><city>Hoddesdon, Hertfordshire EN11 9BU</city><country>GB</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2012026694-W"><document-id><country>US</country><doc-number>2012026694</doc-number><kind>W</kind><date>20120227</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012148555-A1"><document-id><country>WO</country><doc-number>2012148555</doc-number><kind>A1</kind><date>20121101</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549762429" load-source="docdb">AL</country><country mxw-id="DS549840530" load-source="docdb">AT</country><country mxw-id="DS549762430" load-source="docdb">BE</country><country mxw-id="DS549915503" load-source="docdb">BG</country><country mxw-id="DS549773052" load-source="docdb">CH</country><country mxw-id="DS549841685" load-source="docdb">CY</country><country mxw-id="DS549840531" load-source="docdb">CZ</country><country mxw-id="DS549762431" load-source="docdb">DE</country><country mxw-id="DS549841690" load-source="docdb">DK</country><country mxw-id="DS549841691" load-source="docdb">EE</country><country mxw-id="DS549854808" load-source="docdb">ES</country><country mxw-id="DS549915504" load-source="docdb">FI</country><country mxw-id="DS549915505" load-source="docdb">FR</country><country mxw-id="DS549762432" load-source="docdb">GB</country><country mxw-id="DS549841692" load-source="docdb">GR</country><country mxw-id="DS549762441" load-source="docdb">HR</country><country mxw-id="DS549840532" load-source="docdb">HU</country><country mxw-id="DS549773065" load-source="docdb">IE</country><country mxw-id="DS549762442" load-source="docdb">IS</country><country mxw-id="DS549915506" load-source="docdb">IT</country><country mxw-id="DS549841693" load-source="docdb">LI</country><country mxw-id="DS549762221" load-source="docdb">LT</country><country mxw-id="DS549840533" load-source="docdb">LU</country><country mxw-id="DS549762222" load-source="docdb">LV</country><country mxw-id="DS549762223" load-source="docdb">MC</country><country mxw-id="DS549841137" load-source="docdb">MK</country><country mxw-id="DS549841142" load-source="docdb">MT</country><country mxw-id="DS549840542" load-source="docdb">NL</country><country mxw-id="DS549762443" load-source="docdb">NO</country><country mxw-id="DS549841698" load-source="docdb">PL</country><country mxw-id="DS549762224" load-source="docdb">PT</country><country mxw-id="DS549840543" load-source="docdb">RO</country><country mxw-id="DS549762233" load-source="docdb">RS</country><country mxw-id="DS549840544" load-source="docdb">SE</country><country mxw-id="DS549762234" load-source="docdb">SI</country><country mxw-id="DS549762444" load-source="docdb">SK</country><country mxw-id="DS549841699" load-source="docdb">SM</country><country mxw-id="DS549841143" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA101515848" ref-ucid="WO-2012148555-A1" lang="EN" load-source="patent-office"><p num="0000">This invention describes an amidation process whereby perfluorinated amino acids can be activated and treated with an amine in the presence of a coupling agent and a pyridine derivative to yield amides, without loss of optical purity.</p></abstract><abstract mxw-id="PA101781037" ref-ucid="WO-2012148555-A1" lang="EN" source="national office" load-source="docdb"><p>This invention describes an amidation process whereby perfluorinated amino acids can be activated and treated with an amine in the presence of a coupling agent and a pyridine derivative to yield amides, without loss of optical purity.</p></abstract><abstract mxw-id="PA101515849" ref-ucid="WO-2012148555-A1" lang="FR" load-source="patent-office"><p num="0000">Cette invention concerne un procédé d'amidation par lequel des acides aminés perfluorés peuvent être activés et traités avec une amine en présence d'un agent de couplage et un dérivé de pyridine pour donner des amides, sans perte de pureté optique.</p></abstract><abstract mxw-id="PA101781038" ref-ucid="WO-2012148555-A1" lang="FR" source="national office" load-source="docdb"><p>Cette invention concerne un procédé d'amidation par lequel des acides aminés perfluorés peuvent être activés et traités avec une amine en présence d'un agent de couplage et un dérivé de pyridine pour donner des amides, sans perte de pureté optique.</p></abstract><description mxw-id="PDES52291790" ref-ucid="WO-2012148555-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> TITLE OF THE INVENTION </p><p id="p0002" num="0002">AMIDATION PROCESS </p><p id="p0003" num="0003">BACKGROUND OF THE INVENTION </p><p id="p0004" num="0004"> This invention describes an amidation process whereby fluorinated amino acids can be activated and treated with an amine in the presence of a coupling agent and a pyridine derivative to yield amides, without loss of optical purity. The resulting amides are selective cathepsin K inhibitors which can be used in the treatment of osteoporosis and metastatic bone disease. </p><p id="p0005" num="0005"> The art describes the amidation as including a coupling agent and a base, specifically HOBt. Dry HOBt is unstable and potentially explosive, so it would be desirable to develop an amidation process that does not utilize HOBt. </p><p id="p0006" num="0006"> It would also be desirable to have an amidation process that is simpler, less expensive and uses readily available reagents; the instant process meets those needs. </p><p id="p0007" num="0007">Additionally, the instant process produces a higher yield when compared with previously known processes and can be run at lower temperatures. </p><p id="p0008" num="0008">SUMMARY OF THE INVENTION </p><p id="p0009" num="0009"> By this invention, there are provided processes for the preparation of compounds of structural formula I: </p><p id="p0010" num="0010"><img id="imgf000002_0001" he="34" wi="79" file="imgf000002_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0011" num="0011"> I </p><p id="p0012" num="0012">com risin amidating a salt of formula IIA or an acid of formula IIB </p><p id="p0013" num="0013"><img id="imgf000002_0002" he="35" wi="156" file="imgf000002_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0014" num="0014"> IIA IIB </p><p id="p0015" num="0015">with 1-aminocyclopropane carbonitrile, In the presence of a coupling agent, a pyridine derivative and a solvent; </p><p id="p0016" num="0016">wherein Rl is Ci_6 alkyl or Ci_6 haloalkyl; </p><p id="p0017" num="0017">R<sup>2</sup> is C 1-6 alkyl or C\.(, haloalkyl; 
<!-- EPO <DP n="3"/>-->
 2012/026694 </p><p id="p0018" num="0018">R3 is SO<sub>m</sub>(Ci.6 alkyl); </p><p id="p0019" num="0019"> X is a tertiary amine, a secondary amine or a metal salt; and </p><p id="p0020" num="0020">m is an integer from zero to two. </p><p id="p0021" num="0021">DETAILED DESCRIPTION OF THE INVENTION </p><p id="p0022" num="0022"> By this invention, there are provided processes for the preparation of compounds of structural formula I: </p><p id="p0023" num="0023"><img id="imgf000003_0001" he="34" wi="79" file="imgf000003_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0024" num="0024"> I </p><p id="p0025" num="0025">co an acid of formula IIB </p><p id="p0026" num="0026"><img id="imgf000003_0002" he="40" wi="158" file="imgf000003_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0027" num="0027"> IIA IIB </p><p id="p0028" num="0028">with l-aminocyclopropane carbonitrile, in the presence of a coupling agent, a pyridine derivative and a solvent; </p><p id="p0029" num="0029">wherein Ri is Ci-g alkyl or Q.g haloalkyl; </p><p id="p0030" num="0030">R2 is C 1-6 alkyl or Ci_6 haloalkyl; </p><p id="p0031" num="0031">R3 is SO<sub>m</sub>(Ci-6 alkyl); </p><p id="p0032" num="0032"> X is a tertiary amine, a secondary amine or a metal salt; and </p><p id="p0033" num="0033">m is an integer from zero to two. </p><p id="p0034" num="0034"> In <sub>a</sub>n embodiment of the invention, R<sup>1</sup> is Ci<sub>-6</sub> haloalkyl In a class of the invention, R<sup>1</sup> is (2-fluoro,2-methyl)propyl. </p><p id="p0035" num="0035"> In an embodiment of the invention, R<sup>2</sup> is Ci<sub>-6</sub> haloalkyl. In a class of the invention, R<sup>2</sup> is trifluoromethyl. </p><p id="p0036" num="0036"> In an embodiment of the invention, R is S02(Ci-6 alkyl). In a class of the invention, R<sup>3</sup> is SO<sub>2</sub>CH<sub>3</sub>. </p><p id="p0037" num="0037"> In an embodiment of the invention X is a secondary amine. In a class of the invention, X is DCHA. </p><p id="p0038" num="0038"> In an embodiment of the invention, the compound of formula I is 
<!-- EPO <DP n="4"/>-->
</p><p id="p0039" num="0039"><img id="imgf000004_0001" he="46" wi="87" file="imgf000004_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0040" num="0040"> N<sup>1</sup> 1 -cyanocyclopropyl)-4-fluoro-N<sup>2</sup>^ </p><p id="p0041" num="0041">4-yl]ethyl } -L-leucinamide. </p><p id="p0042" num="0042"> An -aminoacid or its corresponding salt is combined with an amine in the presence of a coupling agent and a pyridine derivative. The reaction is run in the presence of a suitable solvent. </p><p id="p0043" num="0043"> In an embodiment of the invention, the coupling agent is selected from the group consisting of a carbodiimide, phosphonium salt or uronium salt. In a class of the invention, the coupling agent is DCC, DIC, EDC, phosphonium iodide, tetramethylphosphonium iodide, PyBrOP, PyAOP, HBTU, HATU, TATU, TBTU and mixtures thereof. In a subclass of the invention, the coupling agent is EDC. </p><p id="p0044" num="0044"> In an embodiment of the invention, the pyridine derivative is selected from the group consisting of pyridine, 4-phenylpyridine, 4-alkylpyridine, 3-alkylpyridine, 3,4- dialkylpyridine, 3- bromopyridine, 4-bromopyridine and mixtures thereof. In a class of the invention, the pyridine derivative is pyridine. </p><p id="p0045" num="0045"> In an embodiment of the invention, the solvent is selected from the group consisting of DMF, DMAc, NMP, acetonitrile, THF, DMSO and mixtures thereof. In a class of the invention, the solvent is DMF. </p><p id="p0046" num="0046"> In an embodiment of the invention is the process for the preparation of a compound of structural </p><p id="p0047" num="0047"><img id="imgf000004_0002" he="51" wi="86" file="imgf000004_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 comprising amidating 
<!-- EPO <DP n="5"/>-->
</p><p id="p0048" num="0048"><img id="imgf000005_0001" he="46" wi="83" file="imgf000005_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes"/></p><p id="p0049" num="0049">with 1-aminocyclopropane carbonitrile, in the presence of EDC, pyridine and DMF. </p><p id="p0050" num="0050"> The term "alkyl" as used herein shall mean a substituting univalent group derived by conceptual removal of one hydrogen atom from a straight or branched-chain acyclic saturated hydrocarbon (i.e., -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, </p><p id="p0051" num="0051"> -CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, -C(CH<sub>3</sub>)<sub>3;</sub> etc.). </p><p id="p0052" num="0052"> As appreciated by those of skill in the art, "halo" or "halogen" as used herein is intended to include chloro, fluoro, bromo and iodo. The term "keto" means carbonyl (C=0). The term "alkoxy" as used herein means an alkyl portion, where alkyl is as defined above, connected to the remainder of the molecule via an oxygen atom. Examples of alkoxy include methoxy, ethoxy and the like. </p><p id="p0053" num="0053"> The term "haloalkyl" means an alkyl radical as defined above, unless otherwise specified, that is substituted with one to five, preferably one to three halogen. Representative examples include, but are not limited to trifluoromethyl, dichloroethyl, and the like. </p><p id="p0054" num="0054"> The term "tertiary amine" includes, but is not limited to, trimethylamine, triethylamine, tripropylamine, dimethylethanolamine and bis-tris. </p><p id="p0055" num="0055"> The term "secondary amine" includes, but is not limited to, dimethyl amine, diethylamine, methylethanolamine, aziridine, azetidine, pyrrolidine, piperidine, and </p><p id="p0056" num="0056">dicyclohexylamine (DCHA). </p><p id="p0057" num="0057"> The term "metal salt" includes, but is not limited to, salts of aluminum, antimony, calcium, copper, gold, iron, lead, lithium, magnesium, platinum, potassium, sodium, silver, strontium, tin, titanium, tungsten and zinc. Preferred metal salts include salts of lithium, sodium, potassium, magnesium, calcium, aluminum and zinc. </p><p id="p0058" num="0058"> The term carbodiimide refers to a class of coupling agents that are often used to activate carboxylic acids towards amide formation. Nonlimiting examples or carbodiimides include: DCC (Ν,Ν'-dicyclohexylcarbodiimide), DIC (Ν,Ν'-diisopropylcarbodiimide) and EDC (l~ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride). </p><p id="p0059" num="0059"> The term phosphonium salt refers to salts containing the phosphonium ion ((PH<sub>4</sub><sup>+</sup>) ion) which are useful as coupling agents. Nonlimiting examples of phosphonium salts include: phosphonium iodide, tetramethylphosphonium iodide, PyBrOP (Bromo-tris-pyrrolidino 
<!-- EPO <DP n="6"/>-->
 T/US2012/026694 phosphoniumhexafluorophosphate) and PyAOP ((7-Azabenzotriazol-l- yloxy)tripyrrolidinophosphonium hexafluorophosphate). </p><p id="p0060" num="0060"> The term uronium salt refers to salts containing the uronium ion. Nonlimiting examples of uronium salts include: HBTU (2-(lH-Benzotriazole-l-yl)-l,l,3,3- tetramethyluronium hexafluorophosphate), HATU (2-(7- Aza- 1 H-benzotriazole- 1 -yl)- 1 , 1 ,3 ,3- tetramethyluronium hexafluorophosphate), TATU ((0-(7-Azabenzotriazole~l-yl)-N,N,N'<sub>}</sub>N'~ tetramethyluronium tetrafluoroborate) and TBTU (2-(lH-Benzotriazole-l-yl)-l<sub>5</sub>l,3,3- tetramethyluronium tetrafluoroborate) . </p><p id="p0061" num="0061"> In the schemes and examples below, various reagent symbols and abbreviations have the following meanings: </p><p id="p0062" num="0062"> DMAc: N,N -Dimethyl acetamide </p><p id="p0063" num="0063"> DCHA: Dicyclohexylamine </p><p id="p0064" num="0064"> MTBE: Methyl-i-butylether </p><p id="p0065" num="0065"> iPAc: Isopropyl acetate </p><p id="p0066" num="0066"> DMF: N, N -Dimethylformamide </p><p id="p0067" num="0067"> THF: Tetrahydrofuran </p><p id="p0068" num="0068"> TEA: Triethylamine </p><p id="p0069" num="0069"> DMSO: Dimethylsulfoxide </p><p id="p0070" num="0070"> NMP: 1 -Methyl-2-pyrrolidinone </p><p id="p0071" num="0071"> CDI: N N'-Carbonyldiirnidazole </p><p id="p0072" num="0072"> HATU: 0-(7-Azabenzotriazol- 1 -yl)-N,N,NTSi'-tetramethyluronium hexafluorophosphate</p><p id="p0073" num="0073">EDC: 1 -Ethyl-3-[3-dimethylaminopropyl]cai-bodiimide hydrochloride </p><p id="p0074" num="0074"> HOBt: jV~Hydroxybenzotriazole </p><p id="p0075" num="0075"> NMM: iV-methyl morphonline </p><p id="p0076" num="0076">Scheme 1 depicts the reaction of a substituted a-amino acid or its salt with an amine in the presence of a coupling agent, an activator and a base to yield the corresponding a amino amide product without epimerization of the a-stereocenter. 
<!-- EPO <DP n="7"/>-->
</p><p id="p0077" num="0077">P T/US2012/026694 
<img id="imgf000007_0001" he="34" wi="118" file="imgf000007_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
</p><p id="p0078" num="0078"><img id="imgf000007_0002" he="34" wi="79" file="imgf000007_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0079" num="0079">The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted. </p><p id="p0080" num="0080">EXAMPLE 1 </p><p id="p0081" num="0081"> 4-FLUORO-N-{(15)-2,2<sub>?</sub>2-TRIFLUORO-l-[4'-(METHYLSULFONYL)BIPHENYL-4- YUJETHYL} -L-LEUCINE DICYCLOHEXYLAMINE SALT 
<!-- EPO <DP n="8"/>-->
</p><p id="p0082" num="0082">12 026694 </p><p id="p0083" num="0083"><img id="imgf000008_0001" he="144" wi="129" file="imgf000008_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0084" num="0084">A 200 mL vessel was charged with 2,2.2-trifluoro-l-[4'- (methyisulphonyl)biphenyl-4-yl]ethane-l,l-diol (9.08 g, 26.2 mmol), F-leucine ethyl ester sulphate salt (8.66 g, 31.5 mmol), potassium carbonate (14.5 g, 104.9 mmol) and methanol (27.3 mL). The mixture was heated to 50°C, aged for 4 h and then cooled to -5°C. </p><p id="p0085" num="0085"> A 500 mL vessel was charged with zinc chloride (7.15 g, 52.5 mmol) and dimethoxyethane (40.9 mL). The mixture was cooled to -10°C and sodium borohydride (3.97 g, 104.9 mmol) charged in a portionwise manner. The mixture was aged at -10°C for 1 h and acetonitrile (63,6 mL) added, maintaining the temperature below 0°C. </p><p id="p0086" num="0086"> The imine mixture was then transferred to the borohydride solution, at such a rate as to maintain the temperature between -5 and +5°C. The reaction was then aged between -5 and +5°C for 1.5 h, quenched by the slow addition of acetone (33.9 mL) and allowed to warm to 20°C. MTBE (60.6 mL), 2M HC1 (181.7 mL) and DI Water (63.6 mL) were charged and the mixture aged for 30 min. The organic phase was separated and the aqueous re-extracted with MTBE (45.4 mL). The two MTBE phases were combined, washed with water (45.4 mL x 4) and 
<!-- EPO <DP n="9"/>-->
 2 026694 diluted with MTBE (139.3 mL). Dicyclohexylamine (5.23g, 28.8 mmol) was then charged over 30 min at 20°C. The product slurry was aged at 20°C for 1 h, filtered and washed with TBME (36.3 mL). After drying in-vacuo at 30°C to constant weight, the title compound was obtained as a white powder. </p><p id="p0087" num="0087">EXAMPLE 2 </p><p id="p0088" num="0088">N-(l-CYANOCYCLOPROPYL)-4-FLUORO-N<sup>2</sup>-{(l<sub>1</sub>?)-2<sub>5</sub>2,2-TRIFLUORO-l-[4'- (METHYLSULFONYL)BIPHENYL-4-YL]ETHYL}-L-LEUCINAMIDE </p><p id="p0089" num="0089">F </p><p id="p0090" num="0090"><img id="imgf000009_0001" he="83" wi="136" file="imgf000009_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0091" num="0091">A round-bottom flask was charged with biphenyl acid'DCHA salt (10.3 g), aminocyclopropane carbonitrile<sup>»</sup>HCl (2.21 g), pyridine (2.46 g) and DMF (85 mL). The thick slurry was stirred at ambient temperature for lh. The slurry was cooled to -10°C and EDC*HC1 (4.47 g) added in one portion. The reaction mixture was aged at -10°C for lh and warmed to - 5°C for 3h. The batch was then warmed to 35°C and aged lh. HPLC analysis showed 99.5% conversion. Aqueous phosphoric acid (100 mL) was added at 35-45°C and the resultant slurry cooled to 20°C. The batch was filtered and washed with 55/45 DMF/water (50 mL) and water (50 mL). The solids were dried in the filter at 40-60°C for 24 hours. The desired crade product was isolated as a white solid (7.57g, 94% yield, &gt;99 %ee, 99.0 wt%). Ή NMR (CD<sub>3</sub>OD) δ 8.17 (bs, 1H), 8.05 (d, 2H, J= 8.5), 7.96 (d, 2H, J- 8.5), 7.80 (d, 2H, J- 8.0), 7.64 (d, 2H, J= 8.0), 4.43 (m, 1H), 3.55 (ddd, 1H, J= 5.0, 8.5, 8.0), 3.18 (s, 3H), 2.84 (bm, 1H), 2.02 (m, 2H), 1.46 (d, 3H, J= 21.5), 1.43 (d, 3H, J- 22.0), 1.36 (m, 2H), 1.07 (m, 1H), 0.94 (m, 1H); <sup>13</sup>C NMR 
<!-- EPO <DP n="10"/>-->
 (CD<sub>3</sub>OD) δ; <sup>J9</sup>F NMR (CD<sub>3</sub>OD) δ -73.2, -136.8; IR (cm<sup>"1</sup>) 3331, 2244, 1687, 1304, 1152; mp 223-224 °C, [ ]<sub>D</sub><sup>20</sup> + 23.3 (c - 0.53, MeOH). 
</p></description><claims mxw-id="PCLM45937324" ref-ucid="WO-2012148555-A1" lang="EN" load-source="patent-office"><claim id="clm-0001" num="1"><!-- EPO <DP n="11"/>--><claim-text/><claim-text>WHAT IS CLAIMED IS: </claim-text><claim-text>A process for preparing a compound of formula I: </claim-text><claim-text> <img id="imgf000011_0001" he="81" wi="170" file="imgf000011_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> IIA IIB </claim-text><claim-text> with 1 -aminocyclopropane carbonitrile, in the presence of a coupling agent, a pyridine derivative and a solvent; </claim-text><claim-text> wherein Rl is Ci-6 alkyl or Ci_6 haloalkyl; </claim-text><claim-text> R.2 is C 1-6 alkyl or Ci-6 haloalkyl; </claim-text><claim-text> R3 j<sub>s</sub> SO<sub>m</sub>(Ci-6 alkyl); </claim-text><claim-text> X is a tertiary amine, a secondary amine or a metal salt; and </claim-text><claim-text> m is an integer from zero to two. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. The process of Claim 1 wherein the pyridine derivative is selected from the group consisting of pyridine, 4-phenylpyridine, 4-aIkylpyridine, 3-alkylpyridine, 3,4- dialkylpyridine, 3- bromopyridine, 4-bromopyridine and mixtures thereof. </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. The process of Claim 2 wherein the pyridine derivative is pyridine. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. The process of Claim 1 wherein the solvent is selected from the group consisting of DMF, DMAc, NMP, acetonitrile, THF, DMSO and mixtures thereof. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. The process of Claim 4 wherein the solvent is DMF. <!-- EPO <DP n="12"/>--> </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. The process of Claim 1 wherein the coupling agent is selected from the group consisting of a carbodiimide, phosphonium salt and uronium salt. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. The process of Claim 6 wherein the coupling agent is selected from the group consisting of DCC, DIC, EDC, phosphonium iodide, tetramethylphosphonium iodide,</claim-text><claim-text>PyBrOP, PyAOP, HBTU, HATU, TATU, TBTU and mixtures thereof. </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. The process of Claim 7 wherein the coupling agent is EDC. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. The process of Claim 1 wherein R<sup>1</sup> is Ci_<sub>6</sub> haloalkyl; R<sup>2</sup> is Cj.6 haloalkyl and R<sup>3</sup> is S0<sub>2</sub>(Ci<sub>-6</sub> alkyl). </claim-text><claim-text>The process of Claim 6 wherein R<sup>1</sup> is (2-fluoro,2-methyl)propyl; R<sup>2</sup> trifluoromethyl and R<sup>3</sup> is SO2CH3. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
